NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Search Results for Trubion Pharmaceuticals Inc


Filter Articles: Clinical News | Consumer News | Business News | All News | More Options

Results 1 - 20      Next >


Refine Search
Display Mode: Context | Summary
Biogen Idec Announces Proposal to Acquire All Outstanding Shares of Facet for $14.50 per Share in Cash
2009 SEP 21 ... of a transaction with Biogen Idec. On August 28, Facet announced a collaboration with Trubion Pharmaceuticals, which Biogen Idec believes reduces the value of Facet, as apparently do ... Biogen Idec Inc. (NASDAQ:BIIB) announced that it has submitted a proposal to the Board of Directors of ...
Subject: Biogen Idec
Price: $3.00
*
Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU-016
2009 SEP 7 ... Research, Protein Therapies, Proteomics, Therapy, Treatment, Trubion Pharmaceuticals, Trubion Pharmaceuticals Inc. This article was prepared by Pain & Central Nervous System Week editors ...
Subject: Protein Therapies
Price: $3.00
*
Reports from M.S. Haydenledbetter and colleagues advance knowledge in lymphoma
2009 JUN 8 ... 2009;15(8):2739-2746). For additional information, contact A.F. Wahl, Trubion Pharmaceutical Inc., 2401 4th Avenue, Suite 1050, Seattle, WA 98121, USA. ... Immunopharmaceuticals, Immunotherapy, Medical Device, Monoclonal Antibodies, Oncology, Pharmaceuticals, Therapies, Treatment. This article was prepared by Biotech Business Week ...
Subject: Lymphoma
Price: $3.00
*
This Global Outlook Series on Genetic Engineering Provides a Collection of Market Briefs and Concise Summaries of Research Findings
2009 NOV 16 ... Bone Formation in GE Finds Application in Obesity Control Trubion Develops Advanced mAbs New Study Reveals microRNA's Role in Heart Failure ... OmniGene Bioproducts BRAIN Takes Over Industrial Biotech Assets of MerLion Pharmaceuticals MTS Health Investors Acquires DNA Diagnostic Center Bayer ...
Subject: Research and Markets
Price: $3.00
*
Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
2009 MAY 25 ... Proteomics, Small Lymphocytic Lymphoma, Therapy, Treatment, Trubion Pharmaceuticals, Trubion Pharmaceuticals Inc. This article was prepared by Biotech Business Week editors from staff ...
Subject: Trubion Pharmaceuticals, Inc.
Price: $3.00
*
Trubion Announces Acceptance of Two Presentations on Its TRU-016 Product Candidate at the 2009 ASH Annual Meeting
2009 NOV 23 ... Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) announced the acceptance of two data presentations ...
Subject: Trubion Pharmaceuticals, Inc.
Price: $3.00
*
Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
2009 JUN 15 ... Pharmacodynamics, Pharmacology, Therapies, Therapy, Treatment, Trubion Pharmaceuticals, Trubion Pharmaceuticals Inc. This article was prepared by Biotech Business Week editors from staff ...
Subject: Chronic Lymphocytic Leukemia
Price: $3.00
*
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
2009 JUL 6 ... Biotechnology Company, Marketing and Licensing Agreements, Trubion Pharmaceuticals, Trubion Pharmaceuticals Inc. This article was prepared by Biotech Business Week editors from staff and ...
Subject: Pharmaceuticals
Price: $3.00
*
Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
2009 MAR 9 ... Trubion Pharmaceuticals Inc. (NASDAQ:TRBN) announced a work-force reduction of approximately 25 percent, or 25 ...
Subject: Biotechnology Business
Price: $3.00
*
Trubion Pharmaceuticals Inc. Reports Second Quarter and First Half 2009 Financial Results
2009 AUG 17 ... Trubion Pharmaceuticals Inc. (NASDAQ:TRBN) announced financial results for its second quarter and six months ended ...
Subject: Pharmaceuticals
Price: $3.00
*
Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
2009 APR 6 ... Systemic Lupus Erythematosus, Therapies, Therapy, Treatment, Trubion Pharmaceuticals, Trubion Pharmaceuticals Inc. This article was prepared by Pain & Central Nervous System Week editors ...
Subject: Lupus
Price: $3.00
*
Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
2009 APR 27 ... Company, Cancer, Cancer Research, Oncology, Therapy, Treatment, Trubion Pharmaceuticals, Trubion Pharmaceuticals Inc. This article was prepared by Biotech Business Week editors from staff ...
Subject: Trubion Pharmaceuticals, Inc.
Price: $3.00
*
Trubion Pharmaceuticals, Inc. Reports First-Quarter 2009 Financial Results
2009 MAY 18 ... Biotechnology Company, Marketing and Licensing Agreements, Trubion Pharmaceuticals, Trubion Pharmaceuticals Inc. This article was prepared by Biotech Business Week editors from staff ...
Subject: Pharmaceuticals
Price: $3.00
*
Trubion Pharmaceuticals, Inc. Reports Fourth Quarter and Year-Ended 2008 Financial Results
2009 MAR 23 ... Marketing and Licensing Agreements, Rheumatoid Arthritis, Trubion Pharmaceuticals, Trubion Pharmaceuticals Inc. This article was prepared by Pain & Central Nervous System Week editors ...
Subject: Trubion Pharmaceuticals Inc.
Price: $3.00
*
Trubion Pharmaceuticals, Inc. Reports Positive Data from Phase 2b Re-treatment Study of TRU-015
2009 NOV 2 ... Rheumatoid Arthritis, Rheumatology, Therapies, Trubion Pharmaceuticals, Trubion Pharmaceuticals Inc. This article was prepared by Pain & Central Nervous System Week editors ...
Subject: Pharmaceuticals
Price: $3.00
*
Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
2009 NOV 16 ... Company, Systemic Lupus Erythematosus, Therapy, Treatment, Trubion Pharmaceuticals, Trubion Pharmaceuticals Inc. This article was prepared by Biotech Business Week editors from staff and ...
Subject: Biotechnology Business
Price: $3.00
*
Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
2009 JUN 1 ... Rheumatism, Rheumatoid Arthritis, Rheumatology, Therapies, Trubion Pharmaceuticals, Trubion Pharmaceuticals Inc. This article was prepared by Pain & Central Nervous System Week editors ...
Subject: Arthritis
Price: $3.00
*
Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
2009 MAY 4 ... Pre-Trials Research, Rituxan, Rituximab, Therapies, Treatment, Trubion Pharmaceuticals, Trubion Pharmaceuticals Inc. This article was prepared by Biotech Business Week editors from staff ...
Subject: B-Cell Lymphoma
Price: $3.00
*
MedPredict's Rheumatology Panel Analyzes Rheumatoid Arthritis, Lupus and Gout Markets and Pipelines Following ACR Conference
2008 DEC 1 ... Savient, Teijin/Ipsen/Takeda Abbott Pharmaceuticals, UCB, Vertex, Wyeth/TMRC, Wyeth/Trubion, and Xoma. This report can be purchased by contacting MedPredict. ...
Subject: Arthritis
Price: $3.00
*
Research reports on arthritis therapy from Trubion Pharmaceuticals provide new insights
2008 DEC 15 ... 2008;30(10):1806-16). For additional information, contact D.J. Burge, Trubion Pharmaceuticals Inc., Seattle, Washington USA.. Publisher contact information for the journal ...
Subject: Arthritis Therapy
Price: $3.00
*

Results 1 - 20      Next >




-----------------------
PR Login